Navigation Links
Lexicon Pharmaceuticals Announces Reacquisition of All Rights to Symphony Icon Programs
Date:8/2/2010

thritis, all of which were discovered by Lexicon's research team.  Lexicon has used its proprietary gene knockout technology to identify more than 100 promising drug targets.  Lexicon has focused drug discovery efforts on these biologically-validated targets to create its extensive pipeline of clinical and preclinical programs.  For additional information about Lexicon and its programs, please visit www.lexpharma.com.

Safe Harbor Statement

This press release contains "forward-looking statements," including statements relating to Lexicon's clinical development of LX1031, LX1032 and LX1033 and the potential therapeutic and commercial potential of LX1031, LX1032 and LX1033. This press release also contains forward-looking statements relating to Lexicon's growth and future operating results, discovery and development of products, strategic alliances and intellectual property, as well as other matters that are not historical facts or information.  All forward-looking statements are based on management's current assumptions and expectations and involve risks, uncertainties and other important factors, specifically including those relating to Lexicon's ability to successfully conduct clinical development of LX1031, LX1032 and LX1033 and preclinical and clinical development of its other potential drug candidates, advance additional candidates into preclinical and clinical development, obtain necessary regulatory approvals, achieve its operational objectives, obtain patent protection for its discoveries and establish strategic alliances, as well as additional factors relating to manufacturing, intellectual property rights, and the therapeutic or
'/>"/>

SOURCE Lexicon Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5

Related medicine technology :

1. Lexicon Presents Data Describing LX4211 Positive Phase 2 Clinical Results and Novel Mechanism of Action for Type 2 Diabetes
2. Lexicon Presents Positive Outcome in IBS Patients Treated With LX1031 and Data Supporting Mechanism of Action
3. Lexicon to Provide Clinical Pipeline Update and Report First Quarter 2010 Financial Results
4. Lexicon to Present at BIO International Convention
5. Lexicon to Present Phase 2 Clinical Data for IBS Drug Candidate at Digestive Disease Week
6. Lexicon Announces Proposed $95 Million Common Stock Offering
7. Lexicon to Report Fourth Quarter and Year End 2009 Financial Results on February 23, 2010
8. Lexicon Pharmaceuticals to Present at the 12th Annual BIO CEO & Investor Conference
9. Lexicon to Host Conference Call and Webcast to Review Top-Line Phase 2 Results From Diabetes Trial
10. Lexicon to Present Positive Top-Line Phase 2 Results for LX1031 in Non-Constipating Irritable Bowel Syndrome at GASTRO 2009
11. Lexicon Announces Positive Phase 2 Results of LX1031 in Non-Constipating Irritable Bowel Syndrome
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/18/2013)...   Polymer Technology Systems, Inc. (PTS) ... to integrate the CardioChek ® PA ... health systems across the country. The CardioChek PA ... through Hanson Medical Systems , offers immediate, ... cholesterol, triglycerides, and glucose. (Logo: ...
(Date:6/17/2013)... Quebec , June 17, 2013 Valeant Pharmaceuticals ... announced today that it has filed a preliminary prospectus supplement ... has today made a similar filing with securities regulatory authorities ... in connection with a public offering of its common ... "Offering"). The Company will also grant to the ...
(Date:6/17/2013)... , June 17, 2013  A little known drug industry ... scrutiny by the U.S. Supreme Court – and a ruling ... could not have come at a better time for New ... from the Rx industry tactic are all too apparent in ... 50+ New Yorkers, state residents are in a near Rx ...
Breaking Medicine Technology:Polymer Technology Systems, Inc. to Provide Point-of-Care Lipid Testing to Aegis Health Group's Hospital Clients 2Polymer Technology Systems, Inc. to Provide Point-of-Care Lipid Testing to Aegis Health Group's Hospital Clients 3Valeant Pharmaceuticals Announces Public Offering Of Common Shares 2Valeant Pharmaceuticals Announces Public Offering Of Common Shares 3Valeant Pharmaceuticals Announces Public Offering Of Common Shares 4Supreme Court Ruling on Rx Industry's Pay-to-Delay-Generics Good News for NY Consumers 2Supreme Court Ruling on Rx Industry's Pay-to-Delay-Generics Good News for NY Consumers 3
... (NYSE Amex: ANX ) today announced the closing ... of its common stock and warrants exercisable for up to ...  The securities sold in the offering were sold in a ... 0.5 of a share at a price to the public ...
... 16, 2011 An analysis of the TRITON-TIMI 38 ... American Heart Association (AHA) Scientific Sessions meeting examined the ... death, myocardial infarction [MI] and stroke) compared to clopidogrel ... in acute coronary syndrome (ACS) patients with ST-segment elevation ...
Cached Medicine Technology:ADVENTRX Announces Closing of Public Offering 2ADVENTRX Announces Closing of Public Offering 3New Analysis of Data Presented at AHA Regarding Effect of Effient® (Prasugrel) on Cardiovascular Events in STEMI Patients According to Timing of PCI 2New Analysis of Data Presented at AHA Regarding Effect of Effient® (Prasugrel) on Cardiovascular Events in STEMI Patients According to Timing of PCI 3New Analysis of Data Presented at AHA Regarding Effect of Effient® (Prasugrel) on Cardiovascular Events in STEMI Patients According to Timing of PCI 4New Analysis of Data Presented at AHA Regarding Effect of Effient® (Prasugrel) on Cardiovascular Events in STEMI Patients According to Timing of PCI 5New Analysis of Data Presented at AHA Regarding Effect of Effient® (Prasugrel) on Cardiovascular Events in STEMI Patients According to Timing of PCI 6New Analysis of Data Presented at AHA Regarding Effect of Effient® (Prasugrel) on Cardiovascular Events in STEMI Patients According to Timing of PCI 7New Analysis of Data Presented at AHA Regarding Effect of Effient® (Prasugrel) on Cardiovascular Events in STEMI Patients According to Timing of PCI 8
(Date:6/18/2013)... By studying one of the most successful ... of successful strategies in his article What We Can ... Study. , The inspirational brand Gollan refers to is ... an impressive 62 million followers (and rising). , The ... Facebook Pages earlier this year. The Facebook data tracking publication ...
(Date:6/18/2013)... Lesbian, Gay, Bisexual and Transgender (LGBT) Pride ... sexual minority youth are still at greater ... according to the Suicide Prevention Resource Center. ... recently published recommendation to improve psychologists, treatment ... improve psychological functioning and reduce depression and ...
(Date:6/18/2013)... system using a person,s DNA was announced as ... London Startup Competition, Europe,s largest technology conference. ... on University of Bristol research by its founders, ... Professor of Bioinformatics in the University,s Department of ... to be one of 16 finalists in the ...
(Date:6/18/2013)... AZ (PRWEB) June 18, 2013 ... Stevie® Award in the Company of the Year category ... last night. , The American Business Awards are the ... the U.S.A. are eligible to submit nominations – public ... , Nicknamed the Stevies for the Greek word for ...
(Date:6/18/2013)... cough outbreaks are more likely to die prematurely even ... in Sweden has found. Women had a 20% higher ... 40%. Women also suffered more complications during and after ... as infant death within the first month of life. ... patients with exposure to whooping cough in childhood, particularly ...
Breaking Medicine News(10 mins):Health News:Casey Gollan Shows What We Can Learn From One of the Best Facebook Pages There Is 2Health News:Casey Gollan Shows What We Can Learn From One of the Best Facebook Pages There Is 3Health News:Sexual minority youth need specialized treatment from therapists 2Health News:CyraCom International, Inc. Honored as a Gold Stevie® Award Winner in 2013 American Business Awards 2Health News:CyraCom International, Inc. Honored as a Gold Stevie® Award Winner in 2013 American Business Awards 3
... MADISON, N.J., Nov. 8 Wyeth (NYSE: WYE ... Suisse First Boston,Healthcare Conference on Tuesday, November 13, 2007 ... Joseph M. Mahady, Senior Vice President,Wyeth and President, Wyeth ... live for investors at, http://www.wyeth.com and available for ...
... Mutual and Ohio Farm Bureau,Federation (OFBF) have announced ... to OFBF,s more than 230,000 members. Effective ... access to,Medical Mutual,s SuperMed provider network, the most ... providers in Ohio. Medical,Mutual and OFBF have worked ...
... for injury, study finds , THURSDAY, Nov. 8 (HealthDay ... medications may cut their risk for fracture, Canadian researchers ... there,s an increased risk of additional fractures, other health ... in osteoporosis patients are hip, spine, and wrist fractures. ...
... Focusing on his experience as a physician in ... Harris, MD, FACP, president-elect of the American College of ... Committee Subcommittee on Regulations, Healthcare and Trade. , ... financial struggles that Medicare payments to physicians played on ...
... Va. (Nov. 8, 2007) Virginia Commonwealth University researchers ... that play a major role in clotting disorders, which ... the lungs and those localized deep in the body ... occur when the effect of thrombin, a protein involved ...
... Nov. 8 Pathwork Diagnostics, a,genomics-based diagnostics company ... Origin Test is the focus of two studies ... Meeting of the Association,for Molecular Pathology (November 7-10, ... help determine a tumor,s origin so that,tissue-specific management ...
Cached Medicine News:Health News:Ohio Farm Bureau Health Plan Awarded to Medical Mutual of Ohio 2Health News:Ohio Farm Bureau Health Plan Awarded to Medical Mutual of Ohio 3Health News:Sticking With Meds Lowers Elderly Fracture Risk 2Health News:Looming Medicare cuts will disproportionately hurt physicians in small practices 2Health News:Researchers identify molecules with interesting anti-clotting properties 2Health News:Studies Investigate Diagnostic Performance and Reproducibility of Pathwork Diagnostics' Tissue of Origin Test 2Health News:Studies Investigate Diagnostic Performance and Reproducibility of Pathwork Diagnostics' Tissue of Origin Test 3
The D.O.R.C. Silicone Oil is an ultra purified silicone oil which leads a maximum interfacial tension and minimizes interactions between tissues, cells and endo-tamponades media. (Sterile, 10 ml.)...
Eftiar® offers the vitreoretinal surgeon a temporary tamponade for efficient re-attachment of the retina, release of subretinal fluid, dissection of fibro-vascular proliferation and controlling r...
Clear Vinyl Urethral Catheters (100% Latex Free)...
100% Silicone Foley Catheter Kits 2-Way...
Medicine Products: